Mycenax Biotech (TWO:4726) — Market Cap & Net Worth
Market Cap & Net Worth: Mycenax Biotech (4726)
Mycenax Biotech (TWO:4726) has a market capitalization of $147.60 Million (NT$4.69 Billion) as of September 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #17812 globally and #912 in its home market, demonstrating a -5.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mycenax Biotech's stock price NT$22.60 by its total outstanding shares 207302900 (207.30 Million). Also see Mycenax Biotech total assets for a full breakdown of the balance sheet.
Mycenax Biotech Market Cap History: 2015 to 2026
Mycenax Biotech's market capitalization history from 2015 to 2026. Data shows change from $314.80 Million to $147.60 Million (-4.92% CAGR). Also see 4726 operating cash flow for how efficiently the company converts equity into cash flow.
Mycenax Biotech Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mycenax Biotech's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Mycenax Biotech for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.41x
Mycenax Biotech's market cap is 0.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $172.10 Million | $318.64 Million | -$188.37 Million | 0.54x | N/A |
| 2018 | $168.50 Million | $211.42 Million | -$274.43 Million | 0.80x | N/A |
| 2019 | $152.18 Million | $390.84 Million | -$218.18 Million | 0.39x | N/A |
| 2020 | $210.30 Million | $665.34 Million | $30.95 Million | 0.32x | 6.80x |
| 2021 | $247.53 Million | $774.27 Million | -$89.86 Million | 0.32x | N/A |
| 2022 | $244.92 Million | $732.28 Million | -$453.63 Million | 0.33x | N/A |
| 2023 | $233.16 Million | $652.62 Million | -$682.85 Million | 0.36x | N/A |
| 2024 | $283.45 Million | $683.92 Million | -$467.12 Million | 0.41x | N/A |
Competitor Companies of 4726 by Market Capitalization
Companies near Mycenax Biotech in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Mycenax Biotech to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Mycenax Biotech by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Mycenax Biotech Historical Marketcap From 2015 to 2026
Between 2015 and today, Mycenax Biotech's market cap moved from $314.80 Million to $ 147.60 Million, with a yearly change of -4.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$147.60 Million | -28.48% |
| 2025 | NT$206.39 Million | -27.19% |
| 2024 | NT$283.45 Million | +21.57% |
| 2023 | NT$233.16 Million | -4.80% |
| 2022 | NT$244.92 Million | -1.06% |
| 2021 | NT$247.53 Million | +17.70% |
| 2020 | NT$210.30 Million | +38.20% |
| 2019 | NT$152.18 Million | -9.69% |
| 2018 | NT$168.50 Million | -2.09% |
| 2017 | NT$172.10 Million | -22.50% |
| 2016 | NT$222.06 Million | -29.46% |
| 2015 | NT$314.80 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Mycenax Biotech was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $147.60 Million USD |
| MoneyControl | $147.60 Million USD |
| MarketWatch | $147.60 Million USD |
| marketcap.company | $147.60 Million USD |
| Reuters | $147.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more